Related Experiment Video
Updated: Jan 2, 2026
06:21
Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
2.0K
Cognitive dysfunction: A growing link between diabetes and Alzheimer's disease
Kavya Jash1, Piyush Gondaliya1, Prathibha Kirave1
1Department of Biotechnology, National Institute of Pharmaceutical Education and Research Ahmedabad, Gandhinagar, Gujarat, India.
Drug Development Research
|December 11, 2019
Summary
Diabetes mellitus (DM) increases Alzheimer
Area of Science:
- Neuroscience
- Endocrinology
- Metabolic Diseases
Background:
- Diabetes mellitus (DM) is a growing global health concern with numerous complications.
- Cognitive dysfunction, including age-related memory impairment, is a significant complication of DM.
- Individuals with DM have a doubled risk of developing cognitive dysfunction compared to the general population.
Purpose of the Study:
- To explore the intricate relationship between diabetes mellitus and Alzheimer's disease (AD).
- To elucidate the shared pathophysiological mechanisms linking DM and AD.
- To review emerging factors such as insulin imbalance, advanced glycation end products, and microRNAs.
Main Methods:
- Literature review of studies investigating the correlation between diabetes and Alzheimer's disease.
- Analysis of factors contributing to neurodegeneration in both conditions.
- Examination of the pathophysiology of amyloid beta (Aβ) plaque formation and tau hyperphosphorylation.
Main Results:
- Shared risk factors and pathophysiological pathways exist between DM and AD.
- Insulin dysregulation, advanced glycation end products, and microRNAs are implicated in both diseases.
- Evidence suggests a strong link between insulin resistance/deficiency in DM and Alzheimer's development.
Conclusions:
- The deepening link between diabetes and Alzheimer's necessitates a comprehensive understanding of their connection.
- Shared mechanisms involving insulin imbalance, AGEs, and miRNAs offer potential therapeutic targets.
- Further research is crucial for developing novel therapeutics to address this comorbidity.
Related Concept Videos
01:26Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
01:19Psychoneuroimmunology: Diabetes and Cancer
373
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
373
01:30Dementia
465
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
465
01:22Alzheimer's Disease: Treatment
715
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
715
01:30Cognitive Development During Adulthood
709
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
709
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
471
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
471